182
Views
0
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiometabolic Conditions - Practice Pearl

Practice pearl: the effect of canagliflozin on HbA1c and blood pressure in patients with type 2 diabetes mellitus

Pages 783-785 | Received 03 Aug 2015, Accepted 18 Sep 2015, Published online: 26 Oct 2015
 

Abstract

Review of: Wilding JPH, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438–444; and Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertension. 2014;16(12):875–882.

Two authors did secondary analyses on the original research data for canagliflozin. Wilding et al. found that the degree of the lowering of the HbA1c in patients was greater in patients with a higher baseline HbA1c. Weir et al. found that the blood pressure lowering seen with canagliflozin was greater if the baseline blood pressures were higher. This shows that canagliflozin will have increased effects in more complicated patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.